Interested in companies with long term potential, ideally managed by an aligned & talented team not investment advice / DYOD

Joined December 2021
Absolutely thrilled by this announcement. Well done Prosus $PRX mgt / board. Will have more to say later, but this is a game changer imo. prosus.com/news/the-group-an…
16
17
5
136
Curious George Cap retweeted
One of the biggest issues we have as a society is platforming and magnifying loud people instead of smart & genuinely good people. It’s a huge reason for a ton of problems.
Stephen A. Smith mocks Lane Johnson for retiring to focus on his mental health
149
993
42
8,281
142,919
Curious George Cap retweeted
Having a “price target” on Bitcoin is like having P/E ratio on your dog
We remain long of Bitcoin and have upped our price target to $1.12M
18
79
4
2,516
76,809
It astounds me that FinX, financial media and people generally continue to treat @billackman as a brilliant investor and champion for shareholders. the great thing about investing is that there is a scorecard, and thus, we can unambigiously describe and compare performance. Ackman's performance over the last ~12 years (the inception of his pubic vehicle) has been abysmal. He has massively underperformd the S&P (~3x vs ~5x over 12 years) despite being effectively levered long for most of that period. Meanwhile, his underperformance has been rewarded with billions and billions from his LPs/shareholders. Bill Ackman should be ridiculed for trying to pose as this generation's Benefit, which he relentlessly markets himself as. He used his great track record when his fund was small to create a huge brand for himself, and then raised huge sums of capital off that huge brand, and he has been an expceptionally poor investor since. He was a brilliant investor, and I even called him generational, but that was a long time ago. So please please please, can we all stop treating Ackman as some sort of investor guru, please??
got it, so @billackman designed a structure that has been terrible for shareholders with $PSHD, but you're ok with the structure he designed with $HHH even though it has many of the same elements. Not sure I agree with your logic there... separately, to your point about being a great compounder from his investing...let's ignore the discount and just look at NAV compounding. PSH NAV on 10/1/14 was $25, today it is $77.18, or a 9.9% CAGR (ignores dividend) over 12 years... Over same time period, SPY has compounded at 14.0%. So $PSHD ~3x while $SPY nearly ~5x... That is a massive massive gap, and its a 12 year period, not some immaterial measurement period. who cares what he did 20+ years ago, it is totally irrelevant. Further, when you consider the fact that $PSHD is effectively a levered long only (because it issues debt to fund investments), that makes the long term track record even more appaling for $PSHD. These are the facts. No subjective opinions here, just the actual performance. Here is my subjective opinion: Ackman is a brilliant marketer, and he was a brilliant investor, but his motivations have changed and he is not aligned with shareholders despite his significant ownership in $PSHD and $HHH because of how his economics accrue between his various entities (i.e. he is better off growing AUM to the benefit of $PS vs buying back shares at $PSHD / $PSUS / $HHH etc.).
1
3
876
Totally unserious people. Should be ridiculed irrespective of politics
Jake and Logan Paul, who live in Puerto Rico to avoid paying U.S. federal income taxes, just got a U.S. taxpayer funded trip to the Pentagon to LARP for literally no reason.
2
467
Curious George Cap retweeted
What a battle Ben! ❤️ You deserve the win, I wish you the best for the rest of the tournament! 🙌🏻 I leave here happy with my level after such a long injury. Thank you for the energy NYC! ⚡️ Always a very special place! 🇺🇸 📸 Getty
1,855
7,226
613
122,894
1,903,605
Absolute class from Carlos in defeat and Tiafoe in victory last night. And there have been so many other wonderful displays of sportsmanship throughout the USO, from top 10 players to unranked players, including qualifiers. It’s been awesome to watch.
He visto el último set del Alcaraz-Shelton y lo que más me impresiona no es que un tío que se ha pegado 4 meses sin jugar un partido llegue en su primer torneo a cuartos del US Open, se vaya al supertiebreak tras ir 2-1 abajo en sets y llegue a estar minibreak arriba. Lo que más me impresiona es que después de todo eso acaba perdiendo y el tío sale con una sonrisa de oreja a oreja. Es que ves la imagen sin contexto y piensas que ha ganado. Hay que tener una cabeza privilegiada para eso. Y haber echado mucho de menos el tenis, claro. Aunque menos de lo que el tenis le ha echado de menos a él 🥚🥚
339
Curious George Cap retweeted
In a previous post which can be found below, I described how Lucy was left nearly completely blind in both eyes as a result of a large left frontal hemorrhage in February. The hemorrhage caused downward herniation, putting bilateral pressure on her optic nerves along with prolonged (~18 hours) elevated intracranial pressure. A hard fall on the right side of her face at the time of injury likely created a traumatic optic neuropathy in her right eye. In response to my post, we received incredible support from the X community including some interesting ideas on how to help Lucy. To that end, I thought to make a more targeted outreach to the community for any advice, ideas or input from experts in the eye, optic nerve, and brain or otherwise who can help her recover her vision, which remains her most challenging limitation both physically and emotionally. Below, I provide some background on her vision and treatment to date. We are incredibly grateful for any ideas you may have. Our goal is to help Lucy and others who have suffered a similar fate by crowdsourcing ideas from the X community. Background Initially, both of Lucy’s pupils were maximally dilated and unreactive to light. Slight light reactivity came back to both eyes in the weeks after the hemorrhage. Initially, she appeared to be able to perceive light in the left eye but not the right. The slight right eye pupillary reactivity decreased to zero approximately six weeks after the injury. Because of the severity of her vision loss and the absence of any other viable therapy, we received emergency FDA authorization in May, three months after the injury, to attempt a novel treatment: injection of Lucy's own mitochondria into her eyes. Details of the procedure and the decision-making that led to our decision to do this therapy are described in a preprint manuscript linked here: researchsquare.com/article/r… The principal rationale for the use of mitochondrial injection was based on her imaging. Optical coherence tomography showed that Lucy's outer retina and photoreceptors were fully intact. The damage was confined to her optic nerves and inner retinal neurons that process visual signals and carry them to the brain. The goal, therefore, was to rescue and enhance the function of her neuronal tissue as much as possible. Animal studies have shown that mitochondria delivered intravitreally cross the inner limiting membrane and are taken up by retinal cells. After careful research into the potential benefits and risks which we believed, after careful analysis, to be low, we chose intravitreal injection in an attempt to place mitochondria directly on the surface of her retinal neurons. Within two days of her injections, Lucy’s pupillary responses improved in both eyes. Importantly, she experienced no inflammation or infection. Visual evoked potentials measured weeks later improved, indicating stronger signal transmission from her retina to her visual cortex. After the procedure, Lucy began reacting to pupillometer and visual examinations when previously they did not disturb her. Because Lucy cannot yet describe precisely what she sees, her increased reaction was itself an important indicator of change. Pupillary responses decreased after a few weeks but remained above pre-injection levels. Given the success and the limitations of this strategy (among them: sourcing mitochondria from muscle biopsy is not a great long-term solution), we are exploring other ways to isolate and administer Lucy's autologous mitochondria, which we are now isolating from autologous stem cells derived from fibroblasts, a process that takes six or so weeks and requires significant management of the cell culture. While transplanted mitochondria may improve the function of existing neurons and supporting cells, they are unlikely to result in optic nerve regeneration. Lucy's retinal ganglion cells have already suffered severe atrophy, so even in the best case this strategy has limitations. In the last two weeks, Lucy's daily visual rehabilitation has begun to produce significant results. She can now reliably track objects both horizontally and vertically when before she could not. At first the objects presented to her had to be illuminated to be seen. More recently, she can track projected images and unilluminated objects. Lucy is far from having functional vision so we are very open to ideas and potential solutions. We welcome ideas posted here on X as well as emails to [email protected]. Thank you!
At midnight on February 6th, earlier this year, the doorbell to our apartment rang. The doorbell was followed by a pounding on the door. I answered the door and a security person in our building handed me his phone. It was my oldest daughter Eloise. She had found my 26-year-old daughter unconscious on the floor of her apartment and had called 911. The EMT team was already there, but they did not know what was wrong with Lucy or to which hospital they would take her. I threw on some clothes and jumped in an Uber heading east toward Brooklyn. (Lucy lived alone in Williamsburg.) On the way, I learned that they were taking her to Elmhurst, a City trauma hospital in Queens. I arrived about five minutes after the ambulance to join Eloise, Lucy’s mom, and a friend, and waited to learn what was wrong. After about 15 minutes, I asked a nurse where she was. I looked over his shoulder to his computer. Next to her name, it said “non-responsive.” I walked into the emergency room and wandered around looking for her until I found her unconscious on a gurney surrounded by several doctors and nurses. By about 2:30am with the results from a CAT scan, Lucy’s doctors had determined that she had a massive brain hemorrhage and would need an emergency hemicraniectomy to release the pressure on her brain and remove the blood from the hemorrhage. I called our wonderful friend and family doctor Eddie Fisher and explained what was going on. He woke up Josh Bederson, Chairman of Neurosurgery at Mount Sinai, to find out more about Zach Hickman, the neurosurgeon on call that night. Dr. Bederson said Hickman was an excellent surgeon, which was comforting as we had no choice. The surgery to save Lucy’s life began around 3:15am and finished around 5:30am. It was successful. The following day, I joined Lucy in an ambulance while she was being transferred to Mount Sinai on Madison Avenue. Later that day, we determined from Lucy’s Oura ring that her hemorrhage had occurred around 9am, which meant that more than 19 hours had passed from the time of the hemorrhage to the completion of the surgery to release the pressure on her brain (I only wish @ouraring had an alert for this kind of a medical event. Imagine it could call a family member if the wearer doesn’t cancel the alert). I later learned that the standard of care is not to do surgery to save a patient with a large brain bleed if more than five hours have passed since the hemorrhage. Even when the surgery is done, I was told that the likely outcome for the patient is a few months in a nursing home and death from pneumonia. When I met Lucy’s doctors, I did my best to inspire them: “Let’s see what can be accomplished if we give her the best care possible and we invest unlimited resources to restore her to life.” And I promised that whatever we learned we would make available to everyone. Dr. Chris Kellner, her neurosurgeon, and Dr. David Putrino, Director of Rehabilitation Innovation for the Mount Sinai Health System have led Lucy’s care team since that day. Words cannot describe the remarkable and compassionate care that she has received beginning with the EMT team and then from nurses, doctors, therapists, and the army of people who have worked to save her and return her to life. To this day, we have a daily Zoom where we discuss her progress and make adjustments to her care. While her care and oversight have been incredible, the learnings for the Mount Sinai team have also been elucidating and will assist in the care of many others. Lucy began in a bad place. She was in a coma for several weeks and then awoke not being able to breathe on her own, unable to walk, see or speak. Over the last six months, she has recovered her cognition – she understands everything including her circumstance – is able to walk a hundred or more steps at a time with assistance, is making progress with sounds, vowels and consonants and the beginnings of speech, but she remains unable to see. Each day, she makes a little progress, and daily progress compounds. Every day I tell her that she just needs to make a little progress and it won’t be long before she is back. We remain optimistic that Lucy will return to normal function. It will likely take years, but I believe it is only a matter of time, hard work, and technological progress, along with some, and perhaps a lot, of divine intervention. Many people have been praying for Lucy and we are incredibly grateful for the prayers and remarkable support she has received. Lucy’s friends have been with her every day since the beginning, and their presence and friendship have saved her life and helped to rebuild and maintain her spirit. And on a very positive note, Lucy’s challenge has brought together our entire modern family who have all been incredibly devoted to her care and recovery. Lucy's vision and other faculties may require some form of brain computer interface, work that is underway at Neuralink, Precision Neuroscience, Science, Synchron, Nudge, and other companies in the space. If you are going to have a devastating brain injury, now is the best time in history for that to happen. We are living in a world when you can be confident that the blind will soon see again. We are going to do everything we can to help make that happen, including by assisting existing companies in the space. With respect to our promise to make Lucy’s care available to others, we have made good progress. In May, a real estate colleague made me aware of a 93% vacant, brand new, 400,000 square foot Class A+ purpose-built biotech facility on West End Avenue between 65th and 66th Streets that missed the market and was available for sale. The Pershing Square Foundation acquired the building 60 days later. We also put under contract an adjoining 130,000 square foot building at 320 West 66th Street that is currently being used by Saturday Night Live for studio space. The building has 35-foot ceilings with massive column-free spaces that can be converted into superb rehabilitation facilities. We will close on the SNL building in December. We are also acquiring an adjoining vacant lot with additional air rights. With just the existing zoning rights, we can add a 150,000 square feet for a total of 680,000 square feet, a lab footprint larger than Rockefeller University, and that’s without including the potential for an upzoning that would allow for substantially more buildable area on the site’s 3.4 acres with spectacular views of the Hudson. Our goal is to build the world’s greatest brain research, rehabilitation, recovery, human optimization, and longevity institute. We have named it The Ackman Oxman Institute or the AOI for lack of a better name, but also to reinforce the point that Neri and I and our family are all-in on the mission. The AOI will be patient-centric. It will not be an academic research institute that produces lots of papers, a Nobel Prize winner or two, but little if any results for patients. We will be laser-focused on cures, treatments, devices, rehabilitation and exercise equipment, and targeted and basic research with a goal of massively accelerating the time from idea to innovation to production to helping a patient. While the AOI will be a non-profit, it will have highly commercial instincts. The AOI will have its own venture funding and will work to develop innovations to create companies that we will seed, assist, and spinout to ensure technologies, treatments, techniques, and drugs get to patients as promptly as possible. On one 3.4 acre campus in what is still the greatest city in the world, we will do neurosurgery, neuroscience, rehabilitation, nutrition, BCI and device development, human trials, hyperbaric oxygen treatments, and life extension programs, and we will mandate and incentivize collaboration among the teams with no silos, politics, bureaucracy, or any other constraint that is inconsistent with the mission. Mount Sinai will be an important partner and deservedly so, but it won’t be our only hospital or medical school partner as we don’t believe any institution has a monopoly on the best ideas or the best talent. We don’t believe in exclusive relationships because that is not in the best interest of patients. Five years ago, we considered launching a brain institute inspired by Neri’s mom who sadly died from Alzheimer’s. We couldn’t make the math work as the real estate was too expensive and we believed it would be too difficult to recruit the best talent from universities to our effort. Since then, the real estate became available at a 70% discount, universities became a much less attractive place to work due to politics outweighing meritocracy, protests that disrupt learning, the curse of antisemitism, and a decline in funding. Fortunately, during the same time, I made sufficient personal economic progress to make the AOI possible. The advance of AI in the last few years will also enable us to greatly accelerate our mission. AI still has a lot to learn about human intelligence and the brain, and the AOI should be at the forefront of the interplay between the brain and AI. Today, I am making a public filing disclosing a gift from Neri and me of ~$400 million or 10,000,000 shares of Pershing Square Inc. (PS) to the AOI. It is very early days for Pershing Square so these shares are intended to anchor the long-term work of the AOI as the shares compound over time while generating what we expect will be a growing stream of quarterly dividends to fund the Institute. We will also be announcing an additional gift of similar and potentially greater size which won’t be in the form of Pershing Square stock to provide the AOI with the short- and intermediate-term runway necessary to enable it to achieve its goal of becoming a self-sustaining institute, which reinvests all of its revenues, royalties, and the economic rewards of company formation to advance the fields of brain health and human longevity. Neri and I have chosen to anchor the funding of the AOI to maintain vision alignment and limit the need for the organization to focus on fundraising. We expect the AOI to be the best-resourced brain, rehab, recovery, and longevity institute in the world. We are grateful to have been able to form a board which includes Dean Kamen (our generation’s Thomas Edison), George Yancopoulus (CEO of Regeneron), James Rothman (Nobel Laureate), Bernardo Sabatini (neuroscientist), Chris Kellner (neurosurgeon), Olivia Flatto (CEO Pershing Square Foundation), Neri Oxman, and myself. We have recently identified a CEO who we expect to announce by October along with other key hires, and are beginning searches for a Chief Scientific Officer, a Chief AI/Technology Officer, a Chief Operating Officer, a Chief Financial Officer, and other key leadership roles. If you find what we are building compelling and want to be part of the leadership team that creates and builds the AOI from a standing start, please send an email to: [email protected] with a short note as to why you believe you can help. Please include your best three ideas for the AOI along with a summary of your background and your most important accomplishments. We promise strict confidentiality to those expressing interest in working with us. We have learned from Lucy that the brain can recover from even catastrophic injury. There is so much more work to be done as the mind is a terrible thing to waste. For details from my Pershing Square SEC filing see: sec.gov/Archives/edgar/data/…
265
240
14
3,669
625,905
There isn’t enough money in the world to satiate this man’s greed or fix his irreparable insecurity. Sad.
This story has none of the hallmarks of truth. First, he uses extraction and root canal interchangeably. Second, you can't just "think" your way into not reacting to pain. Especially when that pain hits the trigeminal nerve (one of the largest and most sensitive cranial nerves sitting literal inches from the brainstem). Pain reflexes react orders of magnitude faster than conscious thought (20-30 milliseconds vs 200-300). I don't care how "badass" you are... your body is going to flinch. Third, what dentist in their right mind is going to drill into somebody's mouth with the chance that person flinches and sends the drill spinning at 400,000 rpm into their tongue? The amount of liability that person would be taking on is ludicrous. I don't think this man realizes the amount of insecurity he projects... And I think that's even sadder than the insecurity itself.
1
321
Curious George Cap retweeted
Couldn't think of a better day to post this piece I have been working on...
2
7
3
58
14,853
$NBIS good reminder of where Jensen stands post $NVDA blowout earnings/guide
$NVDA CEO Jensen Huang on $NBIS “NEBIUS WILL TAKE CARE OF YOU”
1
681
Curious George Cap retweeted
$VISN authoring another $150mm of buybacks on top of the $100mm already announced. That is about 18% of the shares outstanding ex the dividend at the current price. My guess is they utilize it fairly aggressively given their huge cash position and the cheap valuation.
3
1
31
7,490
It says everything about the last decade that we tolerate people like Chamath shamelessly masquerading as anything other than the complete and total fraud/charlatan he is, despite mountains of evidence of him essentially enriching himself by stealing from gullible retail investors (leaving a wake of financial destruction). I want to rip my eyeballs out every time I see this guy spout his pseudo iconoclast bullshit.
Chamath walked away with ~$750M in profits across his SPAC empire, while public investors lost an estimated ~$45B to $50B in peak market value across his 18 total deals. Out of 10 sponsored SPACs and 8 PIPEs, 4 dissolved, multiple went bankrupt (Proterra, Sunlight), and 5 of his 6 completed SPAC mergers dropped 50% to 98% below their $10 issue price.
2
522
Did he block you for this too?
This feels like a "nobel disease". There was a time when he was rewarded so much to be contrarian in the face of euphoric bulls. Maybe he would rather be wrong than right with "the sheep". All his recent (1-2 Years) ideas feel so cross to me. Maybe he just knows something.
2
1
302
i really don't get it...zero snark, just (reasonable?) disagreement. If anything, I think you could accuse me of being overly fawning of @michaeljburry I am just so stunned this would provoke a block...
Replying to @michaeljburry
@michaeljburry did you mean to block me for this? I was complimenting you and saying I was a very happy CU subscriber, I just disagree with you (at the moment on $NBIS). Maybe you missed the part where I said I also really appreciate all your contributions to the idea market place? I'm so confused...
1
1
325
But, are you really on it @BillAckman ? I hope so because it has been a brutal brutal stretch being a $PSH shareholder. Even after Valeant debacle, I still considered you one of the GOAT'ed investors, but lately, you have done a spectacularly job disabusing me of that notion...please give us shareholders a reason to believe again.
Pershing Square $PS announced earnings this evening in advance of our call tomorrow at 9am ET and our Spaces on @X which will follow the call. Please read our letter in advance of the call which explains the quarter and provides updates on the portfolio and six new positions in $NFLX, $V, $MA, $ICE, $ALC, and $SPGI pershingsquareinc.com/wp-con…
4
1,745
yup, and no one seems to be botherd by this. the system is so insanely rigged.
Speaking of taking the gains. Kushner likely has some exits coming up and he’ll get to write off all his cap gains for these investments against depreciation of players contracts etc and essentially pay zero tax ala Ballmer when he bought the clips. All because for whatever reason US sports franchises are granted some absurd tax loopholes.
392
astounding work $NBIS
In light of the recent Michael Burry news, Jim Chanos comments, and recent FUD surrounding $NBIS heading into earnings, we have decided to fully ungate our Nebius price targets and model heading into earnings. Our full report and model are linked in the comments. If you find value from our research and work, consider Northwise Premium as a way to support our work and in order to receive our upcoming new Nebius model scheduled for after earnings. We are committed to independent, quality research and Northwise Members allow us to remain focused on equities rather that partnerships, advertising, or compromising deals. Thanks again for your support, and enjoy!
1
568
Curious George Cap retweeted
$MELI still has 4.6% profit margins while growing 50%+
15
10
253
19,363
cosign this. haven't dug in yet, but if you gave me these results / press release and i had to guess market reaction, I would have expect to see the stock up a few percent, not down ~7%. The market doesn't believe $MELI 's investment are widening the moat, or so it seems. The cynical interpretation is the company's moat is weaker than formerly believed, which is why the company needs to be investing / discounting so aggressively. Top line growth doesn't create value in of itself, but a more charitable interpreation is that the topline growth (which is remarkable) reflects the ecoystem getting stronger, customer relationships deepening, and operate leverage to come. i love the way the company describes its plan to dominate its markets, but at some point they will need to give a little bit to the market to protect its equity cost of capital. showing some margin discipline (~some~) and or repurchasing shares would go a long way here... i'm long the stock...
$MELI quarter is a perfect example of why investing isn’t as simple as margins up = good or margins down = bad. Bears see: • Operating margin DOWN • Net income DOWN • Another quarter of profit compression Bulls see the WHY behind margin compression: • Record revenue (+50%) • Commerce + Fintech engagement accelerating • Free shipping expansion widening moat and customer relations • Logistics buildout • Credit card & lending expansion None of these investments maximize this quarter’s earnings. They’re designed to maximize the size of MercadoLibre’s ecosystem five years from now. The real question isn’t whether margins fell. Management forecasted this and it was fully expected. It’s whether today’s margin sacrifice creates a wider moat, higher customer lifetime value, and substantially greater free cash flow over the next decade. In my opinion, it’s obvious. That’s the investment thesis.
597
more stupidity. it is impossible to read, process and interpret these results in 2 minutes, let alone 2 seconds. And yet, bots report headline numbers that have nothing to do with the prospective business case, and algos do whatever it is that algos do when they instantly scan and digest PRs (and I do mean instantly). i'm not one to blame the "algo boogeymen" - but it would behoove people to remember that companies are worth the discounted value of their cash flows, and last quarter's revenue/EPS alone rarely convey much information. This is especially the case for $WULF (and $CIFR) because the headline numbers reflect the legacy BTC mining business, and not the prospective HPC AI data center business. now, this isn't to say $WULF or $CIFR are buys or not, but rather to remind the jumpy retail investors not to be beholden to the market in the 1-30 seconds after an earnings reports comes out.
$WULF Ouch 🩸 Q2 EPS: $(1.94) vs $(0.22) est Sales: $44.767M vs $46.392M est 🟥 -6.66%
1
407